Glenmark launches fixed-dose combination drug for Asthma

Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India.

The company has launched this FDC under the brand name Indamet®. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.

Alok Malik, Group Vice President & Head, India Formulations – Glenmark Pharmaceuticals Ltd. said, “Indamet®, is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”